The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
IXOA regimen, irinotecan (I), capecitabine (X), oxaliplatin (O), and bevacizumab (A), as first-line therapy for advanced unresectable colorectal cancer (aCRC): Preliminary results.
Jean Alfred Maroun
Research Funding - Roche; Sanofi
Derek J. Jonker
Consultant or Advisory Role - Roche (U); Sanofi (U)
Research Funding - Sanofi
M. Christine Cripps
No relevant relationships to disclose
Rakesh Goel
No relevant relationships to disclose
Timothy R. Asmis
No relevant relationships to disclose
Rachel Anne Goodwin
No relevant relationships to disclose
Nirit Yarom
No relevant relationships to disclose
Horia Marginean
No relevant relationships to disclose